Frontiers in Pharmacology (Sep 2021)

The Essential Oil of Artemisia argyi H.Lév. and Vaniot Attenuates NLRP3 Inflammasome Activation in THP-1 Cells

  • Pengxiao Chen,
  • Pengxiao Chen,
  • Pengxiao Chen,
  • Qi Bai,
  • Qi Bai,
  • Yanting Wu,
  • Yanting Wu,
  • Qiongzhen Zeng,
  • Qiongzhen Zeng,
  • Xiaowei Song,
  • Xiaowei Song,
  • Yuying Guo,
  • Pengjun Zhou,
  • Yao Wang,
  • Xiaofeng Liao,
  • Qiaoli Wang,
  • Zhe Ren,
  • Zhe Ren,
  • Yifei Wang,
  • Yifei Wang

DOI
https://doi.org/10.3389/fphar.2021.712907
Journal volume & issue
Vol. 12

Abstract

Read online

Artemisia argyi H. Lév. and Vaniot is a traditional medical herb that has been used for a long time in China and other Asian counties. Essential oil is the main active fraction of Artemisia argyi H. Lév. and Vaniot, and its anti-inflammatory potential has been observed in vitro and in vivo. Here, we found that the essential oil of Artemisia argyi H. Lév. and Vaniot (EOAA) inhibited monosodium urate (MSU)- and nigericin-induced NLRP3 inflammasome activation. EOAA suppressed caspase-1 and IL-1β processing and pyroptosis. NF-κB p65 phosphorylation and translocation were also inhibited. In addition, EOAA suppressed nigericin-induced NLRP3 inflammasome activation without blocking ASC oligomerization, suggesting that it may inhibit NLRP3 inflammasome activation by preventing caspase-1 processing. Our study thus indicates that EOAA inhibits NLRP3 inflammasome activation and has therapeutic potential against NLRP3-driven diseases.

Keywords